Showing results (101-110 of 119) with videos related to

Sort By:
Pageof 12
European Urology Open Science|August 2, 2021
Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [177Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate CancerJudith Stangl-Kremser, Sazan Rasul, Jeffrey J Tosoian, et al.
BJU International|June 7, 2014
Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patientsIlaria Lucca, Morgan Rouprêt, Luis Kluth, et al.
European Urology|July 18, 2021
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD StudyCora N Sternberg, Daniel Castellano, Johann de Bono, et al.
European Urology Oncology|May 14, 2025
Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate CancerNobuaki Matsubara, Daniel Petrylak, Raffaele Ratta, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2018
PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical ImpactBernhard Grubmüller, Pascal Baltzer, Sabrina Hartenbach, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNANobuaki Matsubara, Johann de Bono, David Olmos, et al.
The Lancet. Oncology|September 14, 2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 studyKarim Fizazi, Gero Kramer, Jean-Christophe Eymard, et al.
European Urology Oncology|July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate CancerNiven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 TrialDaniel P Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.
Clinical Genitourinary Cancer|January 24, 2024
Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter StudyMona Kafka, Giulia Giannini, Nastasiia Artamonova, et al.
Pageof 12